

Taken from:  
[Wirral Oral Anticoagulation Guidelines](#)

	Apixaban	Dabigatran	Edoxaban	Rivaroxaban	VKA Warfarin, phenindione, acenocoumarol
<b>Dose form available</b>	2.5mg and 5 mg tablets	75mg, 110mg and 150mg capsules	15mg, 30mg and 60mg tablets	2.5mg, 10mg, 15mg and 20mg tablets	<b>Warfarin:</b> 0.5mg, 1mg, 3mg, 5mg tablets <b>Phenindione:</b> 10mg, 25mg, 50mg tablets <b>Acenocoumarol:</b> 1mg tablets
<b>Regular therapeutic level monitoring</b>	N/A	N/A	N/A	N/A	INR
<b>Regular monitoring</b>	Renal function	Renal function	Renal function	Renal function	None
<b>Contraindicated where CrCl is 30 - 50ml/min</b>	No	Reduced dose applies	Reduced dose applies	Reduced dose applies	No
<b>Contraindicated where CrCl is 15 - 29ml/min</b>	Reduced dose applies	Contraindicated	Reduced dose applies	Reduced dose applies	No
<b>Contraindicated where CrCl&lt;15ml/min</b>	Yes	Yes	Yes	Yes	No
<b>Use in patients with prosthetic valves</b>	No	No	No	No	Yes
<b>Suitable for dosette dispensing</b>	Yes	No	Yes	Yes	No (due to variable dosing)
<b>Can be crushed and administered via enteral feeding tube</b>	Yes	No	Yes	Yes	Yes
<b>Stroke prevention in valvular AF</b>	No	No	No	No	Yes
<b>Stroke prevention in non-valvular AF</b>	Yes	Yes	Yes	Yes	Yes
<b>VTE prophylaxis post THR and TKR</b>	No*	No*	No	Yes	No
<b>Treatment of DVT/PE*</b>	Yes	Yes (Requires at least 5 days of LMWH treatment before initiation)		Yes	Yes
<b>Prevention of recurrent DVT/PE</b>	Yes	Yes	Yes	Yes	Yes
<b>Treatment and prevention of thromboembolism in other veins</b>	No	No	No	No	Yes
<b>Use post-thrombolysis</b>	No	No	No	No	As per guidelines
<b>Reversal agent</b>	No	Idarucizumab	No	No	Phytomenadione
<b>Cost (£/28 day supply) §</b>	2.5mg bd: £53.20 5mg bd: £53.20	110mg bd: £47.60 150mg bd: £47.60	30mg od: £51.80 60mg od: £51.80	10mg od: £50.40 15mg od: £50.40 20mg od: £50.40	<b>Variable cost due to variable dose and cost of monitoring.</b>

\*Drugs are licensed for this indication but not in WUTH formulary.

Note: VKA, apixaban, dabigatran, edoxaban and rivaroxaban are not recommended for use in patients with both DVT/PE and active cancer.

§Prices taken from Drug Tariff, March 2017.

Review date October 2018

Prices updated by Victoria Vincent, Medicines Optimisation Pharmacist, MLCSU

Prices checked by Lynne Sahlman, Practice Pharmacist, MLCSU